

BC PharmaCare Drug Information

The drug below is being considered for possible coverage under the B.C. PharmaCare program. PharmaCare is a government-funded drug plan that helps British Columbians with the cost of eligible prescription drugs and specific medical supplies. For more information on PharmaCare, visit [Ministry of Health - PharmaCare](#).

PharmaCare reviews each drug for treating a specific illness or medical condition (known as an “indication”). If a decision is made to cover the drug, it will be only for that illness or condition.

In some cases, PharmaCare may cover a drug only for people who have the illness or condition and have not responded to other drugs used to treat that illness or condition.

For more information on PharmaCare’s drug coverage review process, see the last page of this information sheet.

Information about the drug	
Generic name (scientific name)	glecaprevir-pibrentasvir
Brand name	Maviret™
Manufacturer	AbbVie Corporation
Indication	Chronic Hepatitis C
Has the drug been reviewed by the Common Drug Review (CDR)? (see the note below this table.)	Yes For more information about the CDR’s review of glecaprevir-pibrentasvir (Maviret™), you can Search the CDR Reports .
Public input start date	Wednesday October 18, 2017
Public input closing date	Wednesday November 15, 2017 AT MIDNIGHT
How is the drug taken?	Maviret is taken orally (by mouth).
How often is the drug is taken?	Maviret is taken once daily.

Information about the drug	
General drug and/or drug study information	<p>Hepatitis C virus (HCV) infection is a serious and potentially life-threatening liver disease that may lead to liver fibrosis, cirrhosis, liver cancer, liver failure and hepatic encephalopathy (a spectrum of neuropsychiatric abnormalities in patients with liver dysfunction).</p> <p>Patients report that symptoms are variable and, for some, the symptoms can be severe and limit patients' ability to work, manage their home, care for family members and maintain relationships.</p> <p>Maviret™ is a fixed-dose combination of two pan-genotypic direct-acting antiviral agents (DAAs): glecaprevir and pibrentasvir</p> <p>Maviret works by stopping the Hepatitis C virus from multiplying. This helps remove the virus from a patient's blood over time.</p> <p>Studies looked at the following outcomes to determine if Maviret is safe and effective for the treatment of Hepatitis C:</p> <ul style="list-style-type: none"> • Sustained virologic response • Treatment failure • Virologic failure (i.e. on treatment failure or relapse) • Health related quality of life • Patient reported symptoms, such as fatigue • Mortality (all cause and liver-related) • Hepatic-related morbidity outcomes (including histological changes, hepatocellular carcinoma, liver failure, and liver transplant) • Work productivity • Bad reactions • Serious bad reactions • Patients leaving the trial due to bad reactions • Bad reactions of special interest: nausea, fatigue, anemia, pruritis, headache, ALT elevations, elevated bilirubin
Other considerations	None

Note:

The Common Drug Review (CDR) is a national organization that reviews drugs on behalf of Canadian public sector plans when manufacturers want to have the jurisdictions provide coverage for the drugs. For detailed information on B.C. PharmaCare's drug review process, including the role of the CDR in that process, see [The Drug Review Process in B.C. - Overview](#).

Cost of the drug under review compared to other drugs used to treat the same indication			
generic name (Brand Name) of Drug Comparator	PharmaCare Status (if and how the drug is already covered)	Usual Dose	Cost Per Course of Therapy
Drug Comparators for Genotype 1			
glecaprevir-pibrentasvir (Maviret™)	Under Review	Three tablets once daily for: 8 weeks (without cirrhosis plus treatment- naïve or experienced with PRS); 12 weeks (with cirrhosis plus treatment- experienced with PRS, or treatment-naïve with NS5A inhibitor); or 16 weeks (treatment-naïve with NS3/4A inhibitor)	\$44,667 ^b for 8 weeks \$67,000 ^b for 12 weeks \$89,333 ^b for 16 weeks
elbasvir-grazoprevir (Zepatier™) with or without RBV	Limited Coverage	Once daily (RBV: twice daily)	Without RBV: \$42,210 ^b to \$63,315 ^b With RBV: \$91,025 ^b to \$91,928 ^b
asunaprevir (Sunvepra™) with daclatasvir (Daklinza™) for genotype 1b	Limited Coverage	Twice daily (daclatasvir: once daily)	\$89,250 ^b
ombitasvir-paritaprevir- ritonavir and dasabuvir (Holkira™ Pak) with or without RBV ^a	Limited Coverage	Two times daily (RBV: twice daily)	\$58,653 ^a to \$117,306 ^a
ledipasvir-sofosbuvir (Harvoni™) with or without RBV	Limited Coverage	Once daily	\$46,900 to \$140,702
sofosbuvir (Sovaldi™) with peginterferon alfa plus RBV	Limited Coverage	Once daily (peginterferon alfa: once weekly; RBV: twice daily)	\$62,739
daclatasvir (Daklinza™) plus sofosbuvir (Sovaldi™) with or without RBV	Non-Benefit for this genotype	daclatasvir: once daily sofosbuvir: once daily RBV: twice daily	Without RBV: \$95,500 ^b to \$191,100 ^b With RBV: \$196,362 ^b

Cost of the drug under review compared to other drugs used to treat the same indication			
generic name (Brand Name) of Drug Comparator	PharmaCare Status (if and how the drug is already covered)	Usual Dose	Cost Per Course of Therapy
sofosbuvir-velpatasvir (Epclusa®) with or without RBV	Limited Coverage	Once daily for 12 weeks; RBV: 1000 mg per day for patients < 75 kg; 1200 mg for patients > 75 kg	Without RBV: \$63,000 With RBV: \$66,197 to \$ 66,837
Drug Comparators for Genotype 2			
glecaprevir-pibrentasvir (Maviret™)	Under Review	Three tablets once daily for 8 weeks (with cirrhosis), or 12 weeks (without cirrhosis)	\$44,667^b to \$67,000^b
daclatasvir (Daklinza™) plus sofosbuvir (Sovaldi™) with or without RBV	Non-Benefit for this genotype	daclatasvir: once daily sofosbuvir: once daily RBV: twice daily	Without RBV: \$95,500 ^b to \$191,100 ^b With RBV: \$196,362 ^b
sofosbuvir (Sovaldi™) with RBV	Limited Coverage	Once daily (RBV: twice daily)	\$61,039 to \$61,696
sofosbuvir-velpatasvir (Epclusa®) with or without RBV	Limited Coverage	Once daily for 12 weeks; RBV: 1000 mg per day for patients < 75 kg; 1200 mg for patients > 75 kg	Without RBV: \$63,000 With RBV: \$66,197 to \$ 66,837
Drug Comparators for Genotype 3			
glecaprevir-pibrentasvir (Maviret™)	Under Review	Three tablets once daily for 8 weeks (without cirrhosis); 12 weeks (with cirrhosis); or 16 weeks (treatment-experienced with PRS^c)	\$44,667^b for 8 weeks \$67,000^b for 12 weeks \$89,333^b for 16 weeks
elbasvir-grazoprevir (Zepatier™) with sofosbuvir (Sovaldi™)	Non-Benefit for this genotype	Once daily (sofosbuvir: once daily)	\$121,065 ^b
sofosbuvir (Sovaldi™) with RBV	Limited Coverage	Once daily (RBV: twice daily)	\$122,077 to \$123,392
daclatasvir (Daklinza™) plus sofosbuvir (Sovaldi™) with or without RBV	Limited Coverage	daclatasvir: once daily sofosbuvir: once daily RBV: twice daily	Without RBV: \$95,500 ^b to \$191,100 ^b With RBV: \$196,362 ^b

Cost of the drug under review compared to other drugs used to treat the same indication			
generic name (Brand Name) of Drug Comparator	PharmaCare Status (if and how the drug is already covered)	Usual Dose	Cost Per Course of Therapy
sofosbuvir-velpatasvir (Epclusa®) with or without RBV	Limited Coverage	Once daily for 12 weeks; RBV: 1000 mg per day for patients < 75 kg; 1200 mg for patients > 75 kg	Without RBV: \$63,000 With RBV: \$66,197 to \$ 66,837
Drug Comparators for Genotype 4			
glecaprevir-pibrentasvir (Maviret™)	Under Review	Three tablets once daily for 8 weeks (without cirrhosis); or 12 weeks (with cirrhosis)	\$44,667^b to \$67,000^b
elbasvir-grazoprevir (Zepatier™) with or without RBV	Limited Coverage	Once daily (RBV: twice daily)	Without RBV: \$63,315 ^b With RBV: \$91,025 ^b to \$91,928 ^b
ombitasvir-paritaprevir- ritonavir (Technivie™) with or without RBV ^a	Non-Benefit	Once daily (RBV: twice daily)	\$58,653 ^{a,b}
sofosbuvir-velpatasvir (Epclusa®) with or without RBV	Limited Coverage	Once daily for 12 weeks; RBV: 1000 mg per day for patients < 75 kg; 1200 mg for patients > 75 kg	Without RBV: \$63,000 With RBV: \$66,197 to \$ 66,837
Drug Comparators for Genotype 5 and 6			
glecaprevir-pibrentasvir (Maviret™)	Under Review	Three tablets once daily for 8 weeks (without cirrhosis) or 12 weeks (with cirrhosis)	\$44,667^b to \$67,000^b
ledipasvir-sofosbuvir (Harvoni™) with or without RBV	Non-Benefit for this genotype	Once daily	\$46,900 to \$140,702
sofosbuvir-velpatasvir (Epclusa®) with or without RBV	Limited Coverage	Once daily for 12 weeks; RBV: 1000 mg per day for patients < 75 kg; 1200 mg for patients > 75 kg	Without RBV: \$63,000 With RBV: \$66,197 to \$ 66,837

^a RBV (Moderiba™) is provided free of charge from the manufacturer when prescribed in combination with Holkira™ Pak or Technivie™

^b Manufacturer's submitted market price

The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent group called the [Drug Benefit Council \(DBC\)](#) gives advice to the Ministry. The DBC looks at:

- whether the drug is safe and effective
- advice from a national group called the [Common Drug Review \(CDR\)](#)
- what the drug costs and whether it is a good value for the people of B.C.
- ethical considerations involved with covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes PharmaCare coverage decisions by taking into account:

- the existing PharmaCare policies, programs and resources
- the evidence-informed advice of the DBC
- the drugs already covered by PharmaCare that are used to treat similar medical conditions
- the overall cost of covering the drug

For more information about the B.C. Drug Review Process, visit: [The Drug Review Process in B.C. - Overview](#).

This document is intended for information only.

It does not take the place of advice from a physician or other qualified health care provider.